New combinations in the treatment of COPD: rationale for aclidinium–formoterol

Cristoforo Incorvaia1
Marcello Montagni2
Elena Makri1
Erminia Ridolo2

1Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, 2Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

Correspondence: Cristoforo Incorvaia
Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, I Via Bignami, Milan 20100, Italy
Tel +39 02 5799 3289
Fax +39 02 5799 3579
Email cristoforo.incorvaia@gmail.com

Abstract: The current guidelines on chronic obstructive pulmonary disease (COPD) recommend the prominent use of bronchodilators, including long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended only in patients with severe disease or frequent exacerbations. LABA–LAMA combinations are indicated when single bronchodilators are insufficient to control COPD. A number of LABA–LAMA combinations are available, based on twice-daily or once-daily administration according to the 12- or 24-hour duration of action, respectively. The aclidinium–formoterol combination is based on the new LAMA aclidinium bromide, which has a high selectivity for M1 muscarinic receptors and a fast onset of action, and the well-known LABA formoterol. Both drugs require twice-daily administration. The fixed-dose combination of aclidinium 400 μg/formoterol 12 μg has shown in randomized controlled trials fast and sustained bronchodilation that was greater than either monotherapy and provided clinically significant improvements in dyspnea and health status compared with placebo, also reducing the use of rescue medications. The overall incidence of adverse events was low and comparable to placebo. These data define the aclidinium–formoterol fixed-dose combination as a new treatment option for patients with COPD. The need for twice-daily administration could be an apparent disadvantage compared to the available once-daily LABA–LAMA combinations, but the immediately perceived benefit in reducing dyspnea due to the fast onset of action, as well as reported correct patient use and satisfaction with the Genuair inhaler might prove useful in favoring adherence.

Keywords: bronchodilators, COPD, LABA, LAMA, combination, efficacy, safety, inhalation device

Introduction

The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is at present mainly based on bronchodilators, with inhaled corticosteroids (ICS) to be used only in patients with severe disease or frequent exacerbations. Inhaled bronchodilators belong to the two classes of β2-agonists and muscarinic antagonists. The introduction of agents with long duration of action, namely the long-acting β2-agonists (LABAs) and the long-acting muscarinic antagonists (LAMAs), was a landmark in their evolution. These drugs offered clear advantages in terms of patient adherence, being possible to inhale twice daily or once daily (according to a duration of 12 or 24 years) in place of the several inhalations each day required with short-acting β2-agonists and muscarinic antagonists. In the last few years, the array of LABAs and LAMAs has expanded, adding to the first drugs (salmeterol and formoterol as LABAs and tiotropium as a LAMA) several other agents. These include indacaterol, olodaterol, vilanterol as a LABA, and glycopyrronium, aclidinium, and umecyclidinium as LAMAs. Also, LABA-LAMA combinations were introduced that make it easier to take the drugs.
when double bronchodilation is required in patients insufficiently controlled by a single bronchodilator. As of now, the combinations authorized from regulatory agencies are indacaterol–glycopyrronium, umeclidinium–vilanterol, olodaterol–tiotropium, and formoterol–aclidinium. Here, we review the efficacy and safety of formoterol–aclidinium, first appraising the performances of the single components and then of their combination.

**Overview of pharmacology, mode of action, and pharmacokinetics of aclidinium and formoterol and rationale for fixed combination**

Formoterol was introduced in the 1980s as a bronchodilator for the treatment of asthma and COPD. Its characteristics can be summarized in a significant bronchodilator effect through β₂-selective adrenoceptor agonism, occurring within minutes of inhalation and persisting for approximately 12 hours, with no significant development of tachyphylaxis at therapeutic doses. With regard to efficacy, inhaled formoterol was shown to be equivalent to or better than comparable dosages of the conventional β₂-agonists salbutamol, fenoterol, and terbutaline. The prolonged duration of action of formoterol allowed for the first time (shortly followed by salmeterol) a twice-daily dosage regimen, resulting in improved control of nocturnal symptoms by reducing the “morning dip.” Derom et al recently evaluated the lung deposition (that assesses the pulmonary bioavailability of the drug) of different doses of inhaled formoterol via the dry-powder inhaler Turbuhaler® in patients with COPD. The mean pulmonary bioavailability was approximately 24% of the nominal delivered dose, with no correlation between lung deposition and baseline value of forced expiratory volume in 1 second (FEV₁). All formoterol doses significantly increased FEV₁ compared with placebo, while only the higher doses (18 and 36 μg) significantly decreased static lung volumes, such as functional residual capacity and residual volume.

Aclidinium bromide, which is a LAMA with high selectivity for M₁ muscarinic receptors and a fast onset of action, was recently introduced. In preclinical evaluation, aclidinium was compared to tiotropium concerning affinity toward different human muscarinic receptor subtypes, potency in inhibiting the agonist-induced activation of muscarinic receptors, and efficacy and duration of bronchoprotection in experimental models. Aclidinium showed affinity and potency comparable to tiotropium, while the dissociation half-life was 27 hours for tiotropium and 10.7 hours for aclidinium, this requiring twice-daily administration. The pharmacokinetics of aclidinium were evaluated in healthy subjects, who were randomized to receive five single increasing doses from 600 to 6,000 μg or placebo inhaled via dry-powder inhaler, with 7-day washouts. Aclidinium was rapidly converted in plasma into alcohol and carboxylic acid metabolites, and was no longer detectable after 3 hours postdose for all doses. Maximum plasma concentrations were reached within 5–7 minutes for all doses and declined rapidly. Mean elimination half-lives of aclidinium >2,400 μg were approximately 1 hour. Also, the lung deposition after administration by the dry-powder inhaler Genuair® was investigated. A single dose of 200 μg of aclidinium, radiolabeled with ⁹⁹ᵐTc, was administered at a targeted peak inspiratory flow rate of 90 L/min in 12 healthy males (18–63 years old), quantifying drug deposition in the lungs and oropharynx, as well as amounts retained in the inhaler. The mean peak inspiratory flow rate was 79.0±9.4 L/min, and the mean percentages of the metered dose deposited in the whole lung and oropharynx were 30.1±7.3% and 54.7±7.2%, respectively. Deposition of aclidinium occurred in all six lung zones, but was highest in the most central zone. A double-blind, partial crossover study on subjects treated with single doses of aclidinium (50, 300, or 600 μg) or placebo assessed the drug activity on specific airway conductance (sGaw) and airway resistance (Raw). Aclidinium significantly increased sGaw compared with placebo at all assessments and doses, except 50 μg at 1 and 24 hours. Significant decreases in Raw were observed with aclidinium 300 and 600 μg compared with placebo at all assessments. For all end points, there was a significant difference between aclidinium 50 μg and the higher doses (P<0.0001). Aclidinium was not detected in plasma.

The rationale for a fixed combination of aclidinium and formoterol in therapy for COPD is based on the similar onset and duration of action of these drugs and the superior effect of the combination compared with either drug alone.

**Efficacy studies on the fixed combination of aclidinium–formoterol**

The most reliable method to establish the efficacy and safety of drug treatment is the systematic review and meta-analysis. The first Cochrane meta-analysis on formoterol concerned its efficacy as medication for asthma, based on eight studies with 22,604 participants. The authors concluded there was efficacy as a reliever similar to short-acting β₂-agonists and an ability to reduce the number of exacerbations requiring a course of oral CS, but with no evidence to recommend changes to
guidelines that suggest that LABAs should be given only to patients already taking ICS. In fact, differently from COPD, the Global Initiative on Asthma guidelines recommend ICS as first-line treatment. In a Cochrane meta-analysis including both formoterol and salmeterol, 26 randomized controlled trials on a global number of 14,939 COPD patients with mean FEV₁ between 33% and 55% of predicted normal were considered. The two LABAs improved predose FEV₁ by 73 mL more than placebo, improved quality of life, and reduced the number of exacerbations requiring hospitalization. The number of people who had exacerbations requiring a course of oral steroids or antibiotics was also lower among those taking LABAs. Moderate-quality evidence from the 26 studies showed that inhaled LABAs are effective over the medium and long term for patients with moderate-to-severe COPD.

Despite aclidinium’s recent introduction, a Cochrane systematic review is also available for the drug, based on 12 randomized controlled trials with an overall number of 9,547 patients with stable COPD. All but one study included in the meta-analysis were double-blind and scored low on risk of bias. Study durations ranged from 4 to 52 weeks. Participants were prevalently males, with a mean age ranging from 61.7 to 65.6 years, and had moderate-to-severe symptoms at randomization; mean postbronchodilator FEV₁ was between 46% and 57.6% of the predicted normal value. The results of the analysis showed that aclidinium gave significantly greater improvement in predose FEV₁ than placebo and improved quality of life by lowering the St George’s Respiratory Questionnaire (SGRQ) total score, with a mean difference of -2.34 when compared to placebo. Also, aclidinium reduced the number of patients with exacerbations requiring hospitalization. There was no difference in nonfatal serious adverse events between aclidinium and placebo. Compared to tiotropium, aclidinium did not demonstrate significant differences for exacerbations requiring oral steroids or antibiotics, or both, or exacerbation-related hospitalizations.

Due to the recent introduction of the aclidinium–formoterol combination, no meta-analysis on it is available, but large scale controlled trials were performed. In the ACLIFORM-COPD trial, 1,344 patients aged more than 40 years with postbronchodilator FEV₁/forced vital capacity $<$70% and FEV₁ between 30% and 80% of predicted normal were randomized to aclidinium–formoterol via the Genuair/Pressair® inhaler in a 24-week, double-blind, parallel-group, active- and placebo-controlled, multicenter Phase III study; 385 patients received the fixed-dose combination (FDC) aclidinium–formoterol 400/12 μg, 381 received the FDC aclidinium–formoterol 400/6 μg, 385 received aclidinium 400 μg alone, 384 received formoterol 12 μg alone, and 194 received placebo, with all treatments twice daily. After 24 weeks, aclidinium–formoterol 400/12 μg and 400/6 μg achieved significant improvements from baseline in 1-hour postdose FEV₁ versus aclidinium of 125 mL (95% confidence interval [CI] 90–160, $P<0.001$) and 69 mL (95% CI 34–105, $P<0.001$), respectively, and trough FEV₁ versus formoterol of 85 mL (95% CI 51–119, $P<0.001$) and 53 mL (95% CI 19–87, $P<0.01$), respectively. In addition, aclidinium–formoterol 400/12 μg and 400/6 μg led to significant improvement in Transition Dyspnea Index (TDI) score versus placebo ($P<0.001$). Both aclidinium–formoterol twice-daily doses significantly improved bronchodilation versus monotherapy and dyspnea versus placebo.

The AUGMENT COPD trial investigating aclidinium–formoterol for treatment of moderate-to-severe COPD included 1,692 patients with stable COPD, equally randomized to twice-daily treatment with the FDC aclidinium 400 μg–formoterol 12 μg, FDC aclidinium 400 μg–formoterol 6 μg, aclidinium 400 μg, formoterol 12 μg, or placebo administered by Genuair/Pressair in a 24-week double-blind study. The change from baseline to week 24 in 1-hour morning postdose FEV₁ (FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV₁ (FDCs versus formoterol) were the coprimary end points, while secondary end points were changes from baseline in SGRQ total score and improvement in TDI score at week 24. Significantly higher improvements from baseline in 1-hour postdose FEV₁ were observed at study end in patients treated with aclidinium 400 μg–formoterol 12 μg FDC or aclidinium 400 μg–formoterol 6 μg FDC compared with aclidinium (108 mL and 87 mL, respectively; $P<0.0001$). Also, improvements in trough FEV₁ were significantly greater in patients treated with aclidinium 400 μg–formoterol 12 μg FDC versus formoterol; a numerical improvement of 26 mL in trough FEV₁ over formoterol was observed with aclidinium 400 μg–formoterol 6 μg FDC. As well, significant improvements in both SGRQ total and TDI focal scores were observed in the aclidinium 400 μg–formoterol 12 μg FDC group at study end ($P<0.0001$). Table 1 highlights the main findings from the two trials.

Bateman et al performed a pooled analysis of the data from the ACLIFORM and AUGMENT trials. The pooled intent-to-treat population included 3,394 patients. Aclidinium–formoterol 400/12 μg significantly improved TDI focal score versus placebo and both monotherapies at week 24 (all $P<0.05$). Over 24 weeks, significant improvements in
Table 1: Controlled trials on efficacy, safety, and tolerability of the FDC aclidinium–formoterol

<table>
<thead>
<tr>
<th>Authors</th>
<th>Patients (n)</th>
<th>Duration</th>
<th>Aclidinium + formoterol (via Genuair/Pressair)</th>
<th>Control (via Genuair/Pressair)</th>
<th>Results</th>
<th>Safety and tolerability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singh et al21</td>
<td>1,344</td>
<td>24 weeks</td>
<td>400+12 μg 400+6 μg</td>
<td>Placebo 400 μg 12 μg</td>
<td>Both FDCs significantly improved FEV₁ from baseline in 1 hour postdose versus aclidinium, formoterol, and placebo. TDI score was significantly improved with aclidinium + formoterol. Aclidinium + formoterol FDC also improved bronchodilatation compared to monotherapy.</td>
<td>The incidence of TEAEs and SAEs was low and comparable in all groups. No significant differences between treatment groups in ECG, vital signs, and laboratory tests. There were four fatal events, none of which was considered to be related to treatments.</td>
</tr>
<tr>
<td>D’Urzo et al22</td>
<td>1,692</td>
<td>24 weeks</td>
<td>400+12 μg 400+6 μg</td>
<td>Placebo 400 μg 12 μg</td>
<td>Both FDCs improved FEV₁ from baseline in 1 hour postdose compared to aclidinium, formoterol, and placebo. SGRQ total, TDI score, and EXACT-RS scores were improved with aclidinium + formoterol. Both FDCs reduced the use of rescue medications more than other monotherapies and placebo.</td>
<td>The overall incidence of AEs was low and comparable between both FDCs and placebo, while it was lower in monotherapy groups. SAEs and TEAEs were infrequent, and occurred with similar incidences in all groups. Five fatal events were reported, none of which was related to treatments.</td>
</tr>
</tbody>
</table>

Abbreviations: FDC, fixed-dose combination; FEV₁, forced expiratory volume in 1 second; TDI, Transition Dyspnea Index; TEAEs, treatment-emergent adverse events; SAEs, severe AEs; AEs, adverse events; ECG, electrocardiography; SGRQ, St George’s Respiratory Questionnaire; EXACT, Exacerbations of Chronic Pulmonary Disease Tool; RS, respiratory symptoms.

As far as safety and tolerability are concerned, aclidinium is well tolerated and safe for use in COPD. Aclidinium 12 μg twice daily shows an incidence of adverse events similar to placebo. The most frequent drug-related adverse events similar to placebo. In particular, tachycardia and tremor, known as class effects of β₂-agonists, were reported in a very low proportion of patients, with no evident dose relationship. Also in the AUGMENT-COPD trial, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In the AUGMENT-COPD trial, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In the AUGMENT-COPD trial, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In the AUGMENT-COPD trial, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy.

In the Cochrane systematic review on aclidinium already published, there was no difference in serious adverse events between aclidinium and placebo. Also, in studies comparing aclidinium to tiotropium, no significant differences in adverse events were found. A review of all published trials comparing FDCs to monotherapies demonstrated that aclidinium, formoterol, and placebo were well tolerated, with safety profiles similar to those of placebo and monotherapy. In studies comparing FDCs to monotherapies, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In studies comparing FDCs to monotherapies, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In studies comparing FDCs to monotherapies, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy. In studies comparing FDCs to monotherapies, all treatments were well tolerated, with safety profiles similar to those of placebo and monotherapy.
patients with severe COPD or frequent exacerbations. This is mainly due to reports that ICS is associated with increased risk of pneumonia. Recently, Festic and Scanlon reviewed the pertinent literature, confirming that the association of use of ICS and incident pneumonia is substantial and concerned both randomized controlled trials and observational studies, though most studies had a significant risk of bias. The unadjusted higher risk of pneumonia is associated with longer duration of use, more potent ICS compounds, and higher doses. Therefore, in most COPD patients, treatment must be based on LABAs, LAMAs, and their combination. The place of LABA–LAMA combinations in stable patients with COPD was very recently systematically reviewed, and the data were pooled using a network, as well as a traditional direct comparison meta-analysis. A total of 23 trials with 27,172 patients were included in the analysis. From the patient perspective, the most important issue is that LABA–LAMA combinations were associated with a greater reduction in dyspnea, as indicated by improvement in TDI scores, and a greater improvement in quality of life, as assessed by the SGRQ score, than monotherapies. There were no statistically significant differences associated with LABA–LAMA combinations compared with monotherapies in safety outcomes or in severe exacerbations. No direct comparisons between aclidinium–formoterol and the other LABA–LAMA combinations, including indacaterol–glycopyrronium, olodaterol–tiotropium, and vilanterol–umeclidinium, are available yet. Also, specific studies on patient satisfaction and adherence are lacking and need to be performed. According to D’Urzo et al, aclidinium–formoterol has the characteristics to be implemented in clinical practice as part of a patient-focused approach to disease control. Actually, when the first LABAs with very long action were introduced, the expert opinion was that “the incorporation of once-daily dose administration is an important strategy to improve adherence and is a regimen preferred by most patients, which may also lead to enhancement of compliance”. Still, twice-daily administration may also result in an advantage. In fact, the demonstration that aclidinium–formoterol can produce a significant synergistic interaction, expressed by the significant anticipation at 5 minutes postadministration of the bronchodilatory effect (as measured by FEV₁) of the combination, compared with the effect of drugs administered alone, suggested a possible role also in the clinical setting. This was actually demonstrated by significant improvements in overall nighttime and early morning symptom severity and limitation of early morning activities in patients treated with the aclidinium–formoterol combination.

Patient profiles appropriate for the fixed combination of aclidinium–formoterol
It is known that as for any other medical treatment, adherence to inhaled drugs for asthma and COPD is unsatisfactory, negatively affecting disease control and treatment costs. The rate of adherence to prescribed treatments for COPD is currently estimated at approximately 50%. Factors causing nonadherence include patient knowledge/education, inhaler-device convenience and satisfaction, age, adverse effects, and medication costs. Generally, the number of doses to be administered each day is inversely correlated to adherence, and this issue was a major motivation to develop the once-daily LABAs and LAMAs. However, drug formulations satisfying the condition “one fits all” are very rare. The characteristics, attitudes, and preferences of individual subjects make it possible that some patients adhere more to twice-daily than to once-daily administration. As described earlier, patient perception of a fast onset of effect on respiratory symptoms, especially in the early morning, may positively influence adherence to two inhalations a day. In fact, lower adherence has been reported for medications that do not have an immediate effect on symptoms. A further aspect is satisfaction with inhaler devices, which is also positively correlated with improved adherence. A randomized, crossover study assessed patient preference, satisfaction, and critical inhaler-technique errors with the Genuair (to be used twice daily with aclidinium in a single formulation or in combination with formoterol) and the Breezhaler® (to be used once daily with glycopyrronium in a single formulation or in combination with indacaterol). The primary end point was the proportion of patients who preferred the Genuair versus the Breezhaler after 2 weeks, and other end points included overall satisfaction, correct use of the inhalers, and willingness to continue with each device. Of the 110 patients in the intent-to-treat population who indicated an inhaler preference, significantly more patients preferred the Genuair than the Breezhaler (72.7% versus 27.3%, P<0.001). Mean overall satisfaction scores were also greater for the Genuair than for the Breezhaler (5.9 versus 5.3, respectively; P<0.001). The proportion of patients making critical inhaler-technique errors was low with both devices, with no significant difference between them. A recent survey investigated the usability of the Genuair device by elderly patients. After the first test, the device was considered “practical/handy” by 90% of patients and “easy to use” by 89%, and the percentage of patients correctly using the device was 93% after a demonstration...
of the inhalation maneuver, with no differences between patients groups in terms of age, educational level, previous use of devices, or presence of arthritis/arthritis. The authors concluded that the characteristics of the Genuair make it a valid choice in elderly patients, and enable them to cope better with the problems and difficulties that are common to this age-group. These observations show that the need for twice-daily administration may not be necessarily a disadvantage for the aclidinium–formoterol combination.

Conclusion

Treatment with the twice-daily aclidinium 400 μg–formoterol 12 μg FDC provided in controlled trials rapid and sustained bronchodilation that was greater than either monotherapy. Clinically significant improvements in dyspnea and health status were evident compared with placebo. These data confer to the aclidinium–formoterol FDC a role as a new treatment option for patients with COPD. The need of twice-daily administration is an apparent weakness compared to the available once-daily LABA–LAMA combinations, but the immediately perceived benefit in reducing dyspnea due to the fast onset of action might prove useful in increasing adherence. This needs to be investigated by specific studies comparing once-daily and twice-daily LABA–LAMA combinations.

Disclosure

The authors report no conflicts of interest in this work.

References


